RT @headachedoc@twitter.com

Fremanezumab (AJOVY™) joins erenezumab (Aimovig™) showing efficacy (-0.6 migraine days / month vs placebo) in patients with #migraine who had previously experienced inadequate responses to 2 to 4 classes of preventive treatments.
http://bit.ly/2UT7OVP